Gritstone bio Inc., entered into a clinical trial agreement with NCI to evaluate an autologous T-cell therapy expressing a T-cell receptor targeting mutated KRAS in combination with Gritstone’s KRAS-directed vaccine candidate, SLATE-KRAS, in a phase I study. The study will be led by Steven A. Rosenberg, chief of the surgery branch at NCI’s Center for Cancer Research.
Former NCI director Norman “Ned” Sharpless had his portrait unveiled at a ceremony hosted by the Foundation for the National Institutes of Health on the main NIH campus in Bethesda.
